UNIVERSITY OF MASSACHUSETTS AMHERST
Multi-directed prime-pull cancer immunotherapy using super-adjuvant nanoparticles
Multi-directed prime-pull cancer immunotherapy using super-adjuvant nanoparticles is a funding opportunity from UNIVERSITY OF MASSACHUSETTS AMHERST, up to 416468, closing May 31, 2031.
May 31, 2031
(1765d left)Overview
PROJECT SUMMARY/ABSTRACT Vaccination has emerged as a promising frontier for cancer therapy, but two critical barriers remain: first, effective adjuvanticity, and second, productive crosstalk between lymph nodes and tumor. Vaccines consist of a target antigen and an adjuvant, the latter of which activates innate…